285 related articles for article (PubMed ID: 25963890)
1. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
3. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Madera-Pajin R; Yunquera-Romero L; Muñoz-Castillo I
Rev Esp Quimioter; 2018 Feb; 31(1):35-42. PubMed ID: 29376623
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Yin S; Barker L; White JZ; Jiles RB
J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
Front Public Health; 2021; 9():779215. PubMed ID: 34957030
[No Abstract] [Full Text] [Related]
7. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Kawano A; Shigematsu H; Miki K; Ichiki Y; Morita C; Yanagita K; Takahashi K; Dohmen K; Nomura H; Ishibashi H; Shimoda S
Intern Med; 2018 Jun; 57(11):1533-1542. PubMed ID: 29321441
[TBL] [Abstract][Full Text] [Related]
8. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Kattakuzhy S; Wilson E; Sidharthan S; Sims Z; McLaughlin M; Price A; Silk R; Gross C; Akoth E; McManus M; Emmanuel B; Shrivastava S; Tang L; Nelson A; Teferi G; Chavez J; Lam B; Mo H; Osinusi A; Polis MA; Masur H; Kohli A; Kottilil S
Clin Infect Dis; 2016 Feb; 62(4):440-447. PubMed ID: 26503379
[TBL] [Abstract][Full Text] [Related]
9. Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.
AbdelMagid AM; Abbassi MM; Ebeid FS; Farid SF; El-Sayed MH
Clin Ther; 2024 Jan; 46(1):e12-e22. PubMed ID: 37925363
[TBL] [Abstract][Full Text] [Related]
10. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
Uchida Y; Nakamura S; Kouyama JI; Naiki K; Motoya D; Sugawara K; Inao M; Imai Y; Nakayama N; Tomiya T; Hedskog C; Brainard D; Mo H; Mochida S
Sci Rep; 2018 Jun; 8(1):8818. PubMed ID: 29892096
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.
Yang X; Tang Y; Xu D; Zhang G; Xu P; Tang H; Pang L
Virol J; 2021 Jul; 18(1):156. PubMed ID: 34315488
[TBL] [Abstract][Full Text] [Related]
12. Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
Manabe T; Tadokoro T; Nakahara M; Ohura K; Fujita K; Tani J; Morishita A; Ogawa C; Masaki T
Intern Med; 2023 Sep; 62(17):2507-2511. PubMed ID: 36450472
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study.
Serranti D; Nebbia G; Cananzi M; Nicastro E; Di Dato F; Nuti F; Garazzino S; Silvestro E; Giacomet V; Forlanini F; Pinon M; Calvo PL; Riva S; Dodi I; Cangelosi AM; Antonucci R; Ricci S; Bartolini E; Mastrangelo G; Trapani S; Lenge M; Gaio P; Vajro P; Iorio R; D'Antiga L; Indolfi G
J Pediatr Gastroenterol Nutr; 2021 Jan; 72(1):95-100. PubMed ID: 32810039
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of hepatitis C infected patients treated through an integrated care model.
Levin JM; Dabirshahsahebi S; Bauer M; Huckins E
World J Gastroenterol; 2016 Oct; 22(38):8558-8567. PubMed ID: 27784968
[TBL] [Abstract][Full Text] [Related]
15. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
Rattanavipapong W; Anothaisintawee T; Teerawattananon Y
PLoS One; 2018; 13(2):e0193112. PubMed ID: 29466415
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty MI; Elbary AAA; Ramadan M
Ann Gastroenterol; 2019; 32(1):93-98. PubMed ID: 30598598
[TBL] [Abstract][Full Text] [Related]
17. Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017.
Clements KM; Kunte PS; Clark MA; Gurewich D; Greenwood BC; Sefton L; Pratt C; Person SD; Wessolossky MA
Health Serv Res; 2022 Dec; 57(6):1312-1320. PubMed ID: 35466398
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine.
Antoniak S; Chasela CS; Freiman MJ; Stopolianska Y; Barnard T; Gandhi MM; Liulchuk M; Tsenilova Z; Viktor T; Dible J; Wose Kinge C; Akpan F; Minior T; Sigwebela N; Mohamed S; Barralon M; Marange F; Cavenaugh C; Horst CV; Antonyak S; Xulu T; Chew KW; Sanne I; Rosen S;
JGH Open; 2022 Dec; 6(12):894-903. PubMed ID: 36514496
[TBL] [Abstract][Full Text] [Related]
19. Experiences and Perspectives From Women Taking Investigational Therapy for Hepatitis C Virus During Pregnancy.
Kislovskiy Y; Chappell C; Flaherty E; Hamm ME; Cameron FA; Krans EE; Chang JC
Subst Abuse; 2021; 15():11782218211046261. PubMed ID: 34602820
[TBL] [Abstract][Full Text] [Related]
20. Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C.
Tahata Y; Sakamori R; Urabe A; Morishita N; Yamada R; Yakushijin T; Hiramatsu N; Doi Y; Kaneko A; Hagiwara H; Yamada Y; Hijioka T; Inada M; Tamura S; Imai Y; Furuta K; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Commun; 2018 Aug; 2(8):884-892. PubMed ID: 30094400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
